Marker Therapeutics, Inc.
Nasdaq-listed company. Follow earnings, filings, products, capital and the competitive forces moving the company.
What’s moving Marker Therapeutics, Inc. now
Current reporting with the operating signal separated from the noise.
Marker Therapeutics, Inc. Secures $16.1 Million in Private Placement to Advance MT-601 Clinical Study for Lymphoma Treatment
The story matters when it changes Marker Therapeutics, Inc.’s customers, execution, competitive position or capital requirements.
Watch next: confirmation in a company filing, official release or regulator record.Marker Therapeutics, Inc. Announces Pricing of Public Offering of Common Stock
Investors are testing whether Marker Therapeutics, Inc.’s operating performance supports its strategy and valuation.
Watch next: the filing, cash flow, guidance and capital-expenditure plan.Marker Therapeutics, Inc. (MRKR) CEO Peter Hoang on Q1 2020 Results
The story matters when it changes Marker Therapeutics, Inc.’s customers, execution, competitive position or capital requirements.
Watch next: confirmation in a company filing, official release or regulator record.Latest MRKR filings.
Investor-relevant reports are shown first, followed by the company’s other recent official submissions.
Marker Therapeutics, Inc., quarter by quarter.
Results, guidance and earnings coverage are grouped only when the source headline identifies the reporting period.
First quarter
SEARCH Q1 COVERAGE →Second quarter
No verified period-specific item in the current feed.
SEARCH Q2 COVERAGE →Third quarter
No verified period-specific item in the current feed.
SEARCH Q3 COVERAGE →Fourth quarter / full year
No verified period-specific item in the current feed.
SEARCH Q4 COVERAGE →